Mobile

An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the aliskiren 300 mg plus hydrochlorothiazide 25 mg in hypertensive patients not adequately responding to ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005810-39

An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the aliskiren 300 mg plus hydrochlorothiazide 25 mg in hypertensive patients not adequately responding to a 4 week therapy with candesartan 32 mg plus hydrochlorothiazide 25 mg

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that 4 weeks of treatment with aliskiren 300mg plus hydrochlorothiazide 25mg in combination provide an additional mean sitting diastolic blood pressure reduction in hypertensive patients not adequately responding (i.e., MSDBP > 90 mmHg) to 4 weeks of treatment with an agiontensin receptor blocker plus hydrochlorothiazide 25mg in combination (candesartan 32mg plus HCTZ 25mg)

Critère d'inclusion

  • Hypertensive patients not adequately responding to a 4 week therapy with candesartan 32 mg plus hydrochlorothiazide 25 mg

Liens